



COVID-END partners coordination call

Notes from 1 October 2020

<https://zoom.us/j/6163788736>

1. INTRODUCTIONS

a. Jeremy welcomed Kayleigh Kew, the methods editor in Cochrane Central

2. COVID-END NETWORK UPDATES

a. Jeremy welcomed final comments on the authorship policy (see attachment 2)

- i. Stefano suggested notifying COVID-END partners when a new core writing group is struck and Alfonso suggested that the way of operationalizing this is to bring potential new papers to partner calls so that people can comment on the make-up of the core writing group*
- ii. Jeremy concluded that we will now accept the authorship policy as final and encouraged people to flag any issues with its operationalization as new papers are being considered and developed*

b. Cochrane supplement paper (see attachment 3)

i. Jeremy noted that the paper will be published sometime in November

c. Sustaining working group's baseline study verification and survey responses

- i. Safa noted that survey responses are starting to come in*
- ii. ACTION:** Partners who have not yet returned a completed survey response to do this ASAP

3. WHO-ECC19 PAPER

a. Jeremy introduced the background to the WHO ECC-19 paper, pointed to the current outline, and invited reactions (see attachment 4)

- i. Jerry noted that he understands that the paper is focused on evidence synthesis and wasn't suggesting that it be diverted to a deep dive beyond that but that instead in the 'beyond synthesis' section we noted that evidence synthesis sits within entire evidence ecosystem*
- ii. Stefano noted four points: 1) need to recognize that in areas where evidence develops more slowly (post-acute chronic care including rehabilitation, non-pharmacological approaches, health services provision), we need to also search for the best available evidence (not just optimal designs); 2) need to address diversity (e.g., specific groups of consumers, including people with disability); 3) need to address the long-term consequences of COVID-19; and 4) need to note the transition from COVID-relevant to COVID-focused evidence*
- iii. Jeremy noted the need to weave in supporting LMIC capacity*
- iv. Kayleigh suggested grouping the points into themes like geography, infrastructure, process, and state of science*

- v. David Tovey suggested making the connection to WHO-INTEGRATE framework (https://gh.bmj.com/content/4/Suppl_1/e000844)

4. NEWS AND INITIATIVES OF INTEREST TO PARTNERS

Jeremy pointed partners to four upcoming events (BESSI webinar, GIN conference featuring COVID-END partners, Evidence Synthesis Ireland webinar, and 2020 What Works Summit) and one invitation to contribute to a draft template (from ACTS COVID-19 Guidance to Action Collaborative)

a. BESSI Webinar Series

- i. The BESSI Collaboration aim to provide information about planned and completed research into reducing SARS-CoV-2 transmission, and facilitate both novel and replication research. First series is on October 2nd and will be on the science of BESSI and behavioural, environmental, social and systems intervention to prevent viral transmission.

Link to register [here](#)

b. Guidelines International Network (GIN) 2020: Pit Stop in the COVID-19 marathon, a series of online panels on guideline development and implementation.

- i. Sessions 3 and 4 are coming up on October 1st and 2nd.

Link to register [here](#)

c. Evidence Synthesis Ireland Webinar Series

- i. Upcoming webinar on October 15th: What 'matters actually comes to matter' in systematic reviews? The importance of 'thing power' as an analytical concept to synthesize qualitative research evidence on therapy compliance.

Link to register [here](#)

d. 2020 What Works Global Summit

- i. Hosted by The Campbell Collaboration and Danish Center for Social Science Research, will bring together experts, researchers and policymakers interested in evidence-based decision-making.

Live, interactive sessions two or three times a day from October 26th to November 6th.

Link to register [here](#)

e. [ACTS COVID-19 Guidance to Action Collaborative](#)

- i. Finalizing a template that participants will use to foster synergies and cross-fertilization among their efforts to enhance the evidence ecosystem cycle for COVID-19 (and beyond). The Collaborative hopes to cultivate synergies between this work and that of COVID-END and its partners, and input on the template and its use are welcomed.

The working draft template is [here](#)

5. ANY OTHER BUSINESS

a. Jeremy noted the following 'weeks off' with no scheduled COVID-END meetings:

- i. Week of October 12
ii. Week of November 16